logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9765087 B1

PDFFull Text
Date of Patent:
Sep. 19, 2017

Filed:

Apr. 04, 2014

Benzimidazole derivatives

Applicant:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Inventors:

Yao-Ling Qiu, Andover, MA (US);

Ce Wang, Beijing, CN;

Xiaowen Peng, Cambridge, MA (US);

Hui Cao, Belmont, MA (US);

Lu Ying, Shanghai, CN;

Xuri Gao, Newton, MA (US);

Bin Wang, Brighton, MA (US);

Yat Sun Or, Watertown, MA (US);

Assignee:

ENANTA PHARMACEUTICALS, INC., Watertown, MA (US);

Attorneys:

Edgar W. Harlan

Carolyn S. Elmore, Esq.

Elmore Patent Law Group, P.C.

Primary Examiner:

Rebecca Anderson

Assistant Examiner:

Karen Cheng

Int. Cl.
CPC ...
C07D 498/10 (2006.01); C07D 403/14 (2006.01); A61K 31/4184 (2006.01); C07D 401/14 (2006.01); A61K 31/444 (2006.01); C07D 405/14 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 31/496 (2006.01); A61K 31/675 (2006.01); C07D 487/08 (2006.01); A61K 31/506 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); A61K 31/422 (2006.01); C07D 491/107 (2006.01); A61K 31/517 (2006.01); C07D 417/14 (2006.01); A61K 45/06 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 31/427 (2006.01); A61K 31/7056 (2006.01); C07F 9/6558 (2006.01); A61K 31/13 (2006.01);
U.S. Cl.
CPC ...
C07D 498/10 (2013.01); A61K 31/13 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 31/7056 (2013.01); A61K 38/19 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 487/08 (2013.01); C07D 491/107 (2013.01); C07F 9/65583 (2013.01);
Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Find Patent Forward Citations

Loading…